Neurobiology of Aging
Volume 32, Issue 12 , Pages 2142-2151 , December 2011

Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease

  • M.T. Armentero

      Affiliations

    • Interdepartmental Research Center for Parkinson's Disease, IRCCS Neurological Institute “C. Mondino”, Via Mondino 2, 27100 Pavia (PV), Italy
    • Laboratory of Functional Neurochemistry.
    • ,
  • E. Sinforiani

      Affiliations

    • Interdepartmental Research Center for Parkinson's Disease, IRCCS Neurological Institute “C. Mondino”, Via Mondino 2, 27100 Pavia (PV), Italy
    • Alzheimer's Disease Assessment Unit.
    • ,
  • C. Ghezzi

      Affiliations

    • Interdepartmental Research Center for Parkinson's Disease, IRCCS Neurological Institute “C. Mondino”, Via Mondino 2, 27100 Pavia (PV), Italy
    • Laboratory of Functional Neurochemistry.
    • ,
  • E. Bazzini

      Affiliations

    • Interdepartmental Research Center for Parkinson's Disease, IRCCS Neurological Institute “C. Mondino”, Via Mondino 2, 27100 Pavia (PV), Italy
    • Laboratory of Functional Neurochemistry.
    • ,
  • G. Levandis

      Affiliations

    • Interdepartmental Research Center for Parkinson's Disease, IRCCS Neurological Institute “C. Mondino”, Via Mondino 2, 27100 Pavia (PV), Italy
    • Laboratory of Functional Neurochemistry.
    • ,
  • G. Ambrosi

      Affiliations

    • Interdepartmental Research Center for Parkinson's Disease, IRCCS Neurological Institute “C. Mondino”, Via Mondino 2, 27100 Pavia (PV), Italy
    • Laboratory of Functional Neurochemistry.
    • ,
  • R. Zangaglia

      Affiliations

    • Interdepartmental Research Center for Parkinson's Disease, IRCCS Neurological Institute “C. Mondino”, Via Mondino 2, 27100 Pavia (PV), Italy
    • Center for Parkinson's Disease and Movement Disorders.
    • ,
  • C. Pacchetti

      Affiliations

    • Interdepartmental Research Center for Parkinson's Disease, IRCCS Neurological Institute “C. Mondino”, Via Mondino 2, 27100 Pavia (PV), Italy
    • Center for Parkinson's Disease and Movement Disorders.
    • ,
  • C. Cereda

      Affiliations

    • Laboratory of Experimental Neurobiology, IRCCS Neurological Institute “C. Mondino”, Pavia, Italy
    • ,
  • E. Cova

      Affiliations

    • Laboratory of Experimental Neurobiology, IRCCS Neurological Institute “C. Mondino”, Pavia, Italy
    • ,
  • E. Basso

      Affiliations

    • Laboratory of Experimental Neurobiology, IRCCS Neurological Institute “C. Mondino”, Pavia, Italy
    • ,
  • D. Celi

      Affiliations

    • IRCCS Centro Neurolesi “Bonino-Pulejo”, Messina, Italy
    • ,
  • E. Martignoni

      Affiliations

    • Dept. of Clinical Medicine, University of Insubria, Varese/Neurorehabilitation and Movement Disorders Unit, IRCCS Fondazione S. Maugeri, Tradate, Italy
    • ,
  • G. Nappi

      Affiliations

    • Interdepartmental Research Center for Parkinson's Disease, IRCCS Neurological Institute “C. Mondino”, Via Mondino 2, 27100 Pavia (PV), Italy
    • Chair of Neurology, University of Rome “La Sapienza”, Rome, Italy
    • ,
  • F. Blandini

      Affiliations

    • Interdepartmental Research Center for Parkinson's Disease, IRCCS Neurological Institute “C. Mondino”, Via Mondino 2, 27100 Pavia (PV), Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 0382 380416; fax: +39 0382 380448.

Received 8 June 2009 ,Revised 27 October 2009 ,Accepted 7 January 2010.

References 

  1. Asuni AA, Hooper C, Reynolds CH, Lovestone S, Anderton BH, Killick R. GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. Eur. J. Neurosci. 2006;24:3387–3392
  2. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002;103:26–35
  3. Beaulieu JM, Gainetdinov RR, Caron MG. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol. Sci. 2007;28:166–172
  4. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc. Natl. Acad. Sci. USA. 2004;101:2173–2178
  5. Blandini F, Cosentino M, Mangiagalli A, Marino F, Samuele A, Rasini E, et al. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. J. Neural Transm. 2004;111:1017–1030
  6. Blandini F, Sinforiani E, Pacchetti C, Samuele A, Bazzini E, Zangaglia R, et al. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology. 2006;66:529–534
  7. Bove J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx. 2005;2:484–494
  8. Buttrick GJ, Wakefield JG. PI3-K and GSK-3: Akt-ing together with microtubules. Cell Cycle. 2008;7:2621–2625
  9. Bychkov E, Ahmed MR, Dalby KN, Gurevich EV. Dopamine depletion and subsequent treatment with l-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J. Neurochem. 2007;102:699–711
  10. Cho JH, Johnson GV. Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J. Biol. Chem. 2003;278:187–193
  11. Cosentino M, Rasini E, Colombo C, Marino F, Blandini F, Ferrari M, et al. Dopaminergic modulation of oxidative stress and apoptosis in human peripheral blood lymphocytes: evidence for a D1-like receptor-dependent protective effect. Free Radic. Biol. Med. 2004;36:1233–1240
  12. Dekosky ST, Ikonomovic MD, Wang X, Farlow M, Wisniewski S, Lopez OL, et al. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. Ann. Neurol. 2003;53:81–90
  13. Dickey CA, Koren J, Zhang YJ, Xu YF, Jinwal UK, Birnbaum MJ, et al. Akt and CHIP coregulate tau degradation through coordinated interactions. Proc. Natl. Acad. Sci. USA. 2008;105:3622–3627
  14. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem. J. 2008;415:333–344
  15. Ferrer I, Barrachina M, Puig B. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease. Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol. 2002;104:583–591
  16. Giese KP. GSK-3 a player in neurodegeneration and memory. IUBMB Life. 2009;61:516–521
  17. Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, et al. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 2005;93:105–117
  18. Hooper C, Killick R, lovestone S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 2008;104:1433–1439
  19. Hoshi M, Takashima A, Noguchi K, Murayama M, Sato M, Kondo S, et al. Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc. Natl. Acad. Sci. USA. 1996;93:2719–2723
  20. Hye A, Kerr F, Archer N, Foy C, Poppe M, Brown R, et al. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci. Lett. 2005;373:1–4
  21. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 2004;29:95–102
  22. Koh SH, Song C, Noh MY, Kim HY, Lee KY, Lee YJ, et al. Inhibition of glycogen synthase kinase-3 reduces l-DOPA-induced neurotoxicity. Toxicology. 2008;247:112–118
  23. Kvetnoy IM, Hernandez-Yago J, Kvetnaia TV, Khavinson VK, Malinin VV, Yarilin AA, et al. Tau-protein expression in human blood lymphocytes: a promising marker and suitable sample for life-time diagnosis of Alzheimer's disease. Neuro. Endocrinol. Lett. 2000;21:313–318
  24. Kwok JB, Hallupp M, Loy CT, Chan DK, Woo J, Mellick GD, et al. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann. Neurol. 2005;58:829–839
  25. Lai CT, Yu PH. Dopamine and L-B-3,4-dihydroxyphenylalanine Hydrochlorid (l-DOPA)-induced Cytotoxicity towards Catecholaminergic Neuroblastoma SH-SYS5 Cells. Effects of oxidative stress and antioxidative factors. Biochem. Parmacol. 1997;53:363–372
  26. Lin CH, Yeh SH, Lin CH, Lu KT, Leu TH, Chang WC, et al. A role for the PI-3 kinase signaling pathway in fear conditioning and synaptic plasticity in the amygdala. Neuron. 2001;31:841–851
  27. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001;20:27–39
  28. Luna-Munoz J, Garcia-Sierra F, Falcon V, Menendez I, Chavez-Macias L, Mena R. Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz-50 antibody in Alzheimer's disease. J. Alzheimers Dis. 2005;8:29–41
  29. Marksteiner J, Humpel C. Glycogen-synthase kinase-3beta is decreased in peripheral blood mononuclear cells of patients with mild cognitive impairment. Exp. Gerontol. 2009;44:370–371
  30. Mateo I, Infante J, Llorca J, Rodriguez E, Berciano J, Combarros O. Association between glycogen synthase kinase-3beta genetic polymorphism and late-onset Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2006;21:228–232
  31. Mckahn G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939–944
  32. Mollenhauer B, Trenkwalder C, Von Ahsen N, Bibl M, Steinacker P, Brechlin P, et al. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement. Geriatr. Cogn. Disord. 2006;22:200–208
  33. Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J. 2002;21:281–293
  34. Nagao M, Hayashi H. Glycogen synthase kinase-3beta is associated with Parkinson's disease. Neurosci. Lett. 2009;449:103–107
  35. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, et al. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 1999;58:1010–1019
  36. Pigino G, Morfini G, Pelsman A, Mattson MP, Brady ST, Busciglio J. Alzheimers presenilin 1 mutations impair kinesin-based axonal transport. J. Neurosci. 2003;23:4499–4508
  37. Plattner F, Angelo M, Giese KP. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 2006;281:25457–25465
  38. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat. Med. 2004;10(Suppl.):S10–S17
  39. Serenó L, Coma M, Rodríguez M, Sánchez-Ferrer P, Sánchez MB, Gich I, et al. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol. Dis. 2009;35:359–367
  40. Shah SB, Nolan R, Davis E, Stokin GB, Niesman I, Canto I, et al. Examination of potential mechanisms of amyloid-induced defects in neuronal transport. Neurobiol. Dis. 2009;36:11–25
  41. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer disease. Science. 2005;307:1282–1288
  42. Telford G, Wilkinson LJ, Hooi DSW, Worrall V, Green AC, Cook DL, et al. An in vitro investigation of the effects of the nerve agent pretreatment pyridostigmine bormide on human peripheral blood T-cell function. Int. Immunopharmacol. 2004;4:1455–1466
  43. Timmons S, Coakley MF, Moloney AM, O’Neil C. Akt signal transduction dysfunction in Parkinson's disease. Neurosci. Lett. 2009;Oct1. [Epub ahead of print], PMID: 19800394
  44. Uberti D, Lanni C, Racchi M, Govoni S, Memo M. Conformationally altered p53: a putative peripheral marker for Alzheimer's disease. Neurodegener. Dis. 2008;5:209–211
  45. Valencia A, Reeves PB, Sapp E, Li X, Alexander J, Kegel KB, et al. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease. J Neurosci Res. 2010;88:179–190
  46. Xiromerisiou G, Hadjigeorgiou GM, Papadimitriou A, Katsarogiannis E, Gourbali V, Singleton AB. Association between AKT1 gene and Parkinson's disease: a protective haplotype. Neurosci. Lett. 2008;436:232–234

PII: S0197-4580(10)00033-3

doi: 10.1016/j.neurobiolaging.2010.01.004

Neurobiology of Aging
Volume 32, Issue 12 , Pages 2142-2151 , December 2011

Article Tools

* Image Usage & Resolution